Advanced Development of Multivalent Filovirus Vaccines

Information

• Research Project
• 8161292

• ApplicationId

  8161292

• Core Project Number

  272200800056C-2-0-1

• Full Project Number

  272200800056C-2-0-1

• Serial Number

  0

• FOA Number

• Sub Project Id

• Project Start Date

  9/30/2008 - 17 years ago

• Project End Date

  9/29/2013 - 12 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2010

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• Crucell Holland B.V.

This contract supports advanced development of a of multivalent filovirus (Ebola and Marburg) vaccine through cGMP manufacturing with an option for a Phase 1 clinical trial. Additional options provide for large scale production, development of a lyophilized formulation and a Phase 2 clinical trial.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  20885825

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:20885825\

• Funding Mechanism

  Contracts, Extramural

• Study Section

• Study Section Name

• Organization Name

  CRUCELL HOLLAND, BV

• Organization Department

• Organization DUNS

  415960780

• Organization City

  LEIDEN

• Organization State

• Organization Country

  NETHERLANDS

• Organization Zip Code

  2333 CN

• Organization District

  NETHERLANDS